Cyclic Amine Carbamoyl Lipids for Astrocyte mRNA Delivery
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing nucleic acid delivery technologies, such as lipid nanoparticles, face challenges in efficiently delivering nucleic acids like mRNA into target cells, particularly astrocytes, which are crucial for treating astrocyte-related diseases, and require improved cellular uptake and protection from degradation.
Innovation Solution
Development of carbamoyl and urea lipids with cyclic amines, which form the basis of novel lipid nanoparticles, enhancing cellular uptake and protection of nucleic acids, specifically mRNA, for targeted delivery and expression in astrocytes.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional lipids are used in lipid nanoparticles, then the nanoparticles can be formed, but the cellular uptake efficiency is insufficient and protection from degradation is inadequate
Solution Approach 1:
The patent modifies the chemical structure of lipids by changing parameters such as introducing cyclic amine groups (piperidine, diazepane) and adjusting the carbamoyl/urea linkage structure. These structural parameter changes enhance the cationic character and interaction with nucleic acids, improving cellular uptake efficiency while maintaining nanoparticle formation capability
Solution Approach 2:
The patent creates composite lipid structures combining carbamoyl/urea linkages with cyclic amine groups and fatty acid chains. This composite approach integrates multiple functional elements (nucleic acid binding, cellular uptake enhancement, stability) into a single lipid molecule, resolving the contradiction between improved performance and manufacturing complexity
2Productivity
If lipid nanoparticles are designed for enhanced cellular uptake, then delivery efficiency improves, but protection from serum degradation may be compromised
Solution Approach 1:
The patent applies local quality by creating different regions within the lipid nanoparticle structure: the cationic lipid portion provides strong nucleic acid binding and cellular uptake, while the fatty acid chains provide hydrophobic interactions for stability. This localized functional distribution allows simultaneous achievement of delivery efficiency and protection from degradation
3Adaptability or versatility
If existing lipid formulations are used, then the basic delivery function is achieved, but targeted delivery to astrocytes and protein expression is not realized
Solution Approach 1:
The patent segments the lipid nanoparticle formulation into specific functional components: carbamoyl/urea lipids with cyclic amines for cellular uptake, complementary lipids for stability, and encapsulated nucleic acids for protein expression. This segmentation allows optimization of each component for its specific function while achieving the overall goal of targeted delivery to astrocytes and protein expression
Data Source
Figure 1
AI summary
The present invention addresses the problem of creating a carbamoyl lipid or a urea lipid each having a cyclic amino and developing lipid nanoparticles, and thereby providing a pharmaceutical composition for nucleic acid therapeutics and others. The present inventors have discovered a compound that is a carbamoyl lipid or a urea lipid each having a cyclic amino or a salt of the compound, and have studied on lipid nanoparticles that can be used in various pharmaceutical compositions. As a result, it was revealed that lipid nanoparticles can be formed using the compound of the present invention, which is a lipid, or a salt of the compound. By using the lipid nanoparticles containing the carbamoyl lipid or the urea lipid each having a cyclic amino according to the present invention, it is expected that a pharmaceutical composition containing the lipid nanoparticles each encapsulating a nucleic acid therein can be used as a prophylactic or therapeutic agent for astrocyte-related diseases.